Company
Proteomics International Laboratories Ltd
ASX:PIQ
Proteomics International Laboratories Ltd is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The company specialises in proteomics – the industrial scale study of the structure and function of proteins.
37 stories · page 1 of 2
Proteomics International to collaborate with University of Melbourne and Royal Women’s Hospital to develop a test for endometriosis
The collaboration aims to build on a Proteomics study that identified protein ‘fingerprints’ in the blood - known as biomarkers - that could be used to test for endometriosis.
Proteomics International engages Abcam to manufacture PromarkerD reagents
According to the company, securing a supply agreement with Abcam and implementing other necessary processes are an essential part of its commercialisation strategy aimed at delivering PromarkerD in global markets.
Proteomics International Laboratories secures Indonesian patent for its diagnostic test
Concurrently, TGA regulatory approval granted for PromarkerD software as an in vitro diagnostic for export use.
Proteomics International to present at diabetes conference featuring PromarkerD test
In parallel with the global roll-out of PromarkerD to markets, the company is pursuing registration of the kit version of the test for larger-scale adoption.
Proteomics International Laboratories set to ship first commercial batch of its immunoassay kit
PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease.
Proteomics International Laboratories boosts balance sheet with sale of CPR Pharm Services stake
An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
Proteomics International Laboratories to reveal results
The halt will remain in place until Wednesday 14th June 2017.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories targets first sales in 2017
Prototype manufacture on target for mid-2017, sales end of 2017.
Aspire Mining [JOHN TO UPDATE] Proactive's Spotlight CEO Sessions
Find out more from David Paull at Proactive's CEO Spotlight Sessions.
Dimerix brings Phase II clinical trials to Proactive's Spotlight CEO Sessions
Find out more from Kathy Harrison at Proactive's CEO Spotlight Sessions.
Novogen [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Dr James Garner at Proactive's CEO Sessions.
Proteomics International to outline pathway to market at Proactive's CEO Sessions
Find out more from Richard Lipscombe at Proactive's CEO Sessions.
Southern Gold brings gold production to Proactive's Spotlight CEO Sessions
Find out more from Simon Mitchell at Proactive's CEO Sessions.
Intermin Resources [JOHN TO UPDATE] at Proactive's Spotlight CEO Sessions
Find out more from Jon Price at Proactive's CEO Spotlight Sessions.
Proteomics International Laboratories to bring PromarkerD to Asia
Proteomics is a global leader in predictive diagnostics.
Proteomics International Laboratories raises funds for diabetic kidney test
Proteomics International Laboratories (ASX:PIQ) has raised $574,500 at $0.24 per share via a share purchase plan to existing shareholders.
Proteomics International Laboratories Ltd to raise cash
Proteomics International Laboratories Ltd (ASX:PIQ) has been granted a trading halt by the ASX this morning, pending details of a capital raising.